Sanofi Reports meta-analysis Data for Nivolumab in Eosinophilic esophagitis

Sanofi today announced meta-analysis results for nivolumab in patients with eosinophilic esophagitis. The study demonstrated that nivolumab demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of eosinophilic esophagitis and support the continued development of nivolumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.